Alteogen Files Domestic Priority Application for Hyaluronidase-Based 'Subcutaneous Injection ADC'

Alteogen announced on the 2nd that it has filed a domestic priority application for a subcutaneous (SC) formulation of antibody-drug conjugates (ADC). This invention relates to formulations and treatments for ADC therapeutics administered subcutaneously using hyaluronidase, modeled on ADC products equipped with highly toxic substances (payloads) such as microtubule inhibitors.

Alteogen Headquarters and Research Center View [Photo by Alteogen]

Alteogen explained that existing ADC therapeutics have been developed and marketed at safe doses reduced from the maximum therapeutic dose due to side effects caused by the strong toxicity of the payload conjugated to the antibody. The company has been exploring the possibility of developing subcutaneous ADC therapeutics by focusing on the pharmacokinetic properties of a new hyaluronidase, ALT-B4, to overcome the limitations of existing drugs and develop more effective treatments. Unlike intravenous injection of ADC therapeutics, which introduces a large amount of drug into the body at once and may cause side effects, subcutaneous administration allows for controlled drug input.

In this process, research was conducted on controlling the amount of hyaluronidase contained in the ADC therapeutics, and based on this, a priority application was filed. It is expected that this approach will enable the development of safer ADC therapeutics with enhanced treatment efficacy. Furthermore, considering that ADCs are developed for relatively few targets and only the first or best-in-class therapeutics in each category are chosen by the market, subcutaneous ADC therapeutics that provide convenience to patients and better treatment outcomes are expected to be competitive.

An Alteogen representative stated, “The company is approaching ADC subcutaneous formulations with a two-track strategy of technology licensing and in-house development. This patent can strengthen the competitiveness of our own pipeline ALT-P7, which targets human epidermal growth factor receptor (HER) 2, and we are conducting research to expand to other ADC therapeutics in the future, which is expected to help reinforce the company’s strategy.”